Last updated: February 15, 2026
What is NDC 72888-0023?
NDC 72888-0023 is a Tiotropium Bromide inhalation aerosol used for managing Chronic Obstructive Pulmonary Disease (COPD). It is marketed under the brand Spiriva Respimat. As a prescription respiratory drug, it has a significant presence in COPD and asthma treatment protocols.
Current Market Environment
Market Size
- The global COPD drugs market was valued at approximately USD 13.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4-5% through 2027 (source: IQVIA, 2022).
- Tiotropium-based therapies account for roughly 15-20% of the COPD pharmacotherapy market, with Spiriva Respimat holding an estimated 70% share among LAMA (long-acting muscarinic antagonists) drugs.
Competitive Landscape
- Major competitors include:
- Ipratropium (short-acting)
- Umeclidinium/Vilanterol (glycopyrronium-based)
- Aclidinium
- Innovator: Boehringer Ingelheim markets Spiriva Respimat; Novartis offers generics and competing inhalers.
Market Penetration & Adoption
- Steady growth observed in U.S. and European markets.
- Adoption favored by prescribing guidelines emphasizing long-acting bronchodilators for COPD.
- The inhaler’s ease of use and established safety profile support market stability.
Pricing Landscape
Existing Price Points
- Patent status: Spiriva Respimat lost patent exclusivity in 2018, enabling generic competition.
- Current U.S. average wholesale price (AWP): Estimated USD 400–450 for a 30-day supply.
- Generic versions: Priced roughly 20-30% lower than the brand; typical AWP range USD 300–350.
Factors Influencing Price Trends
- Patent expiration: Accelerates price erosion due to generic entry.
- Manufacturing costs: Improvements in production processes reduce costs, encouraging price reductions.
- Discounting practices: PBMs and insurance plans negotiate rebates, lowering patient out-of-pocket costs.
- Regulatory changes: FDA policies aiming to improve inhaler device affordability could influence future pricing brackets.
Price Projections (Next 3-5 Years)
| Year |
Market Price Range (USD) |
Key Factors Influencing Price |
| 2023 |
350–450 (brand), 250–350 (generic) |
Increased generic availability, price competition |
| 2024 |
330–430 |
Patent expirations for secondary patents, increased generics |
| 2025 |
310–410 |
Further generic proliferation, rebate negotiations |
| 2026 |
290–390 |
Market stabilization at lower prices, potential biosimilar entry |
| 2027 |
270–370 |
Market maturity, pricing plateau likely |
Potential Influences on Price Declines
- Entry of biosimilars or new inhalation technologies may alter competitive dynamics.
- Insurance reimbursement policies intended to control costs.
- Market saturation in mature markets.
Regulatory & Policy Impact
- The FDA’s push to lower inhaler costs could lead to price caps or incentive programs.
- Changes in patent laws and exclusivity periods directly impact generic market penetration.
- International pricing strategies may differ, especially in emerging markets where affordability drives access.
Strategic Considerations for Stakeholders
- Investors should monitor patent expiry dates and pipeline development.
- Manufacturers can leverage cost reductions for competitive pricing.
- Payers may negotiate rebates to optimize formulary positioning.
Key Takeaways
- NDC 72888-0023 (Spiriva Respimat) commands a robust market share in COPD treatments but faces imminent pricing pressure due to patent expiration.
- Global COPD drug market growth sustains demand, yet generic competition is expected to significantly lower prices.
- Price erosion is forecasted at roughly 20-30% over five years, driven by increased generic availability and policy measures.
- Market stabilization at lower price points is likely; however, innovations in inhalation technology could modify future trends.
- Regulatory actions and patent landscapes will shape pricing strategies; stakeholders should adapt accordingly.
FAQs
1. When did patent protection for Spiriva Respimat expire?
2021, leading to increased generic entry and price competition.
2. How much cheaper are generics compared to the brand?
Typically 20-30% lower, with some discounts reaching 40% in competitive markets.
3. What are the main drivers for future price declines?
Patent expirations, increased generics, and policy interventions.
4. How does the inhaler device affect pricing?
Device manufacturing costs, ease of use, and regulatory approvals influence pricing and market acceptance.
5. Are biosimilars expected for inhalation therapies?
Not yet for small-molecule inhalers like Tiotropium; biosimilar development targets biologics primarily.
Sources:
[1] IQVIA. (2022). Global COPD Market Reports.
[2] FDA. (2022). Inhaler Device Regulations.
[3] Boehringer Ingelheim. (2023). Spiriva Respimat Product Information.
[4] MarketWatch. (2023). Respiratory Drugs Pricing Trends.
[5] Novartis. (2022). Generic Strategies in Respiratory Medicine.
